NexGenix Pharmaceuticals (US-New York) Drug Class: Small molecule Mechanism/Technology: NexGenix' platform is based on hypothesis that chaperone activity is linked to the aggregation process observed in many neurodegenerative diseases. Chaperone proteins can be involved in facilitating both refolding and clearance of abnormally folded proteins. Hsp90 inhibition facilitates the degradation of mutated pathogenic client proteins. Primary Indication: Cancer and neurodegenerative diseases Stage: Preclinical
